Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
- ProName: Sorafenib
- CasNo:284461-73-0
- Molecular Formula: C21H16ClF3N4O3
- Appearance: white powder
- Application: Pharma intermediates
- DeliveryTime: 3days
- PackAge: 1kg/pack
- Port: Shanghai Port
- ProductionCapacity: 10000 Metric Ton/Day
- Purity: 99%min
- Storage: dry and cool place
- Transportation: By Air，By TNT,EMS,Fedex
- LimitNum: 100 Gram
No comments:
Post a Comment